A single-center pilot study evaluating the safety and efficacy of a preemptive short course of glecaprevir/pibrentasvir in hepatitis C positive to negative kidney transplantation

Brief description of study

The purpose of this research study is to evaluate the feasibility of a 2 week course of glecaprevir/pibrentasvir (Mavyret) starting immediately prior to transplantation to treat hepatitis C virus (HCV) in kidney transplant recipients who receive a kidney from a donor with HCV. Mavyret is a combination pill with two medicines (glecaprevir and pibrentasvir) to treat HCV infection. It has been shown to effectively treat HCV Infection in non-transplantation and in transplantation patients with success rates of >98% (more than 98 out of 100). Although Mavyret is approved by the Food and Drug Administration (FDA) for treatment of established HCV infection when taken for 8 weeks, its use in transplant patients for a 2 week duration is not approved, and therefore, is investigational.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.